Targeting a Uniquely Nonspecific Prenyl Synthase with Bisphosphonates to Combat Cryptosporidiosis

被引:30
作者
Artz, Jennifer D. [1 ]
Dunford, James E. [2 ,3 ]
Arrowood, Michael J. [4 ]
Dong, Aiping [1 ]
Chruszcz, Maksymilian [5 ]
Kavanagh, Kathryn L. [2 ]
Minor, Wladek [5 ]
Russell, R. Graham G. [3 ]
Ebetino, F. Hal [6 ]
Oppermann, Udo [2 ,3 ]
Hui, Raymond [1 ]
机构
[1] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada
[2] Univ Oxford, Struct Genom Consortium, Oxford OX3 7DQ, England
[3] Univ Oxford, Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Oxford OX3 7LD, England
[4] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA
[5] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA
[6] Procter & Gamble Pharmaceut Inc, Mason, OH 45040 USA
来源
CHEMISTRY & BIOLOGY | 2008年 / 15卷 / 12期
基金
英国惠康基金;
关键词
D O I
10.1016/j.chembiol.2008.10.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cryptosporidiosis is a neglected disease without a wholly effective drug. We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length determinant region enables it to accommodate larger substrates and products. These results, combined with existing data on their clinical use, demonstrate that N-BPs are very promising anticryptosporidial drug candidates.
引用
收藏
页码:1296 / 1306
页数:11
相关论文
共 56 条
[21]   A molecular ruler for chain elongation catalyzed by octaprenyl pyrophosphate synthase and its structure-based engineering to produce unprecedented long chain trans-prenyl products [J].
Guo, RT ;
Kuo, CJ ;
Ko, TP ;
Chou, CC ;
Liang, PH ;
Wang, AHJ .
BIOCHEMISTRY, 2004, 43 (24) :7678-7686
[22]   CryptoDB:: a Cryptosporidium bioinformatics resource update [J].
Heiges, Mark ;
Wang, Haiming ;
Robinson, Edward ;
Aurrecoechea, Cristina ;
Gao, Xin ;
Kaluskar, Nivedita ;
Rhodes, Philippa ;
Wang, Sammy ;
He, Cong-Zhou ;
Su, Yanqi ;
Miller, John ;
Kraemer, Eileen ;
Kissinger, Jessica C. .
NUCLEIC ACIDS RESEARCH, 2006, 34 :D419-D422
[23]   Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis [J].
Hosfield, DJ ;
Zhang, YM ;
Dougan, DR ;
Broun, A ;
Tari, LW ;
Swanson, RV ;
Finn, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (10) :8526-8529
[24]   The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs [J].
Kavanagh, Kathryn L. ;
Guo, Kunde ;
Dunford, James E. ;
Wu, Xiaoqiu ;
Knapp, Stefan ;
Ebetino, Frank H. ;
Rogers, Michael J. ;
Russell, R. Graham G. ;
Oppermann, Udo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (20) :7829-7834
[25]   The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding [J].
Kavanagh, Kathryn L. ;
Dunford, James E. ;
Bunkoczi, Gabor ;
Russell, R. Graham G. ;
Oppermann, Udo .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (31) :22004-22012
[26]   Structure and reaction geometry of geranylgeranyl diphosphate synthase from Sinapis alba [J].
Kloer, Daniel P. ;
Welsch, Ralf ;
Beyer, Peter ;
Schulz, Georg E. .
BIOCHEMISTRY, 2006, 45 (51) :15197-15204
[27]   PROCHECK - A PROGRAM TO CHECK THE STEREOCHEMICAL QUALITY OF PROTEIN STRUCTURES [J].
LASKOWSKI, RA ;
MACARTHUR, MW ;
MOSS, DS ;
THORNTON, JM .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1993, 26 :283-291
[28]   Bisphosphonates: A review of their pharmacokinetic properties [J].
Lin, JH .
BONE, 1996, 18 (02) :75-85
[29]   Bisphosphonate inhibitors of Toxoplasma gondi growth:: In vitro, QSAR, and in vivo investigations [J].
Ling, Y ;
Sahota, G ;
Odeh, S ;
Chan, JMW ;
Araujo, FG ;
Moreno, SNJ ;
Oldfield, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (09) :3130-3140
[30]   The Farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates [J].
Ling, Yan ;
Li, Zhu-Hong ;
Miranda, Kildare ;
Oldfield, Eric ;
Moreno, Silvia N. J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (42) :30804-30816